3 recruiting, 1 completed, 1 withdrawn. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Xospata: new trials by email Literature Review of Xospata trials Research Report on Xospata
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Azacitidine, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 70 | 2023-07-25 | 2026-09-17 |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies ERAS-007, ERAS-601, Gilteritinib - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Erasca, Inc. | 2022-03-15 | 2022-06-15 | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. Gilteritinib, Idarubicin, Cytarabine - Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Astellas Pharma Inc | 97 | 2015-02-26 | 2025-09-02 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
Leukemia, Myeloid, Acute (5) · Blast Crisis (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myelodysplastic Syndromes (1) · Recurrence (1)
Astellas Pharma Inc (1) · Erasca, Inc. (1) · French Innovative Leukemia Organisation (1) · M.D. Anderson Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (3) · France (1) · Japan (1) · South Korea (1) · Taiwan (1)
Hiroto Inaba, MD, PhD (1) · Les Brail, Ph.D. (1) · Tapan M Kadia (1)
PMID 29702001, PMID 34329576, PMID 40193193, PMID 40500616, PMID 41835842